Bicara Therapeutics Inc. – Material Contracts Watch

from 10-K 23 pages Bicara Therapeutics Inc. 2026 Inducement Plan

from 10-K 3 pages Bicara Therapeutics Inc. Amended & Restated Non-Employee Director Compensation Policy

from 10-Q 5 pages Second Amendment to Office Lease Agreement

from 10-Q 17 pages Whereas, Landlord, as Tenant, Has Leased Suite 701, Purporting to Consist of 9,682 Feet of Rentable Area (The “Premises”) in the Building Located at 116 Huntington Avenue, Boston, Massachusetts (The “Building”) From Columbia REIT – 116 Huntington, LLC, a Delaware Limited Liability Company (The “Prime Landlord”) by Lease Dated July 30, 2019 (The “Prime Lease”); and Whereas, Landlord Has Agreed to Sublet to Tenant the Premises, and Tenant Has Agreed to Sublet the Premises From Landlord. Now Therefore, Landlord and Tenant, in Consideration of the Mutual Covenants Herein Contained and Each With Intent to Be Legally Bound, for Themselves and Respective Successors and Assigns, Hereby Agree as Follows: 1. Sublease

from 10-Q 26 pages First Amendment to Office Lease Agreement

from S-1/A 3 pages Bicara Therapeutics Inc. Non-Employee Director Compensation Policy

from S-1/A 34 pages Bicara Therapeutics Inc. Indemnification Agreement

from S-1/A 10 pages Bicara Therapeutics Inc 2024 Employee Stock Purchase Plan

from S-1/A 40 pages Bicara Therapeutics Inc. 2024 Stock Option and Grant Plan

from S-1 54 pages Definitions

from S-1 45 pages Clinical Trial Collaboration and Supply Agreement

from S-1 19 pages Contract Transfer and License Agreement

from S-1 7 pages Bicara Therapeutics Inc. Compensation Recovery Policy

from S-1 17 pages This [Second]2 Amended and Restated Employment Agreement (“Agreement”) Is Made Between Bicara Therapeutics Inc., a Delaware Corporation (The “Company”), and [Name] (The “Executive”), and Is Effective Commencing on [ ] (The “Effective Date”). Except With Respect to the Equity Documents and Restrictive Covenants Agreement (Both as Defined Below) and Subject to Section 11 Below, This Agreement Supersedes in All Respects All Prior Agreements Between the Executive and the Company Regarding the Subject Matter Herein, Including Without Limitation (I) the Employment Agreement Between the Executive and the Company Dated [ ], [As Amended by the First Amendment to Employment Agreement Dated [ ],And the Amended and Restated Employment Agreement Dated [ ]]3 (Collectively, the “Prior Agreements”), and (II) Any Other Offer Letter, Employment Agreement or Severance Agreement. Whereas, the Company Desires to Continue to Employ the Executive and the Executive Desires to Continue to Be Employed by the Company on the Terms and Conditions Contained Herein. Now, Therefore, in Consideration of the Mutual Covenants and Agreements Herein Contained and Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Is Hereby Acknowledged, the Parties Agree as Follows: 1. Employment

from S-1 3 pages Bicara Therapeutics Inc. Senior Executive Cash Incentive Bonus Plan

from S-1 59 pages Bicara Therapeutics Inc. 2019 Stock Option and Grant Plan

from DRS 54 pages Definitions

from DRS 45 pages Clinical Trial Collaboration and Supply Agreement

from DRS 19 pages Contract Transfer and License Agreement

from DRS 58 pages Bicara Therapeutics Inc. 2019 Stock Option and Grant Plan